Related Experiment Video
Updated: Aug 9, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 2, 2013
Molecular pathology of low malignant bladder transitional cell carcinoma: a current perspective
1Department of Urology, Tianjin Institute of Urologic Surgery, The Second Hospital of Tianjin Medical University, HeXi District, TianJin, China. peterrock2000@126.com
Abstract:
Bladder transitional cell carcinoma (BTCC) actually has two phenotypes: low malignant and aggressive. Most previous molecular and cytogenetic analyses of bladder cancer were focused on aggressive BTCC. Little is known about the events that lead to the development of low malignant BTCC. This review mainly introduces the concept of two types of bladder tumors and then focuses on the molecular pathology of low malignant BTCC in particular. It is hoped that further understanding of the molecular pathology of low malignant BTCC may provide novel therapies and many other clinical benefits in patients with this disease.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cellular Adaptation IV: Dysplasia and Metaplasia

